Literature DB >> 456406

Clofibrate disposition in renal failure and acute and chronic liver disease.

R Gugler, J W Kürten, C J Jensen, U Klehr, J Hartlapp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 456406     DOI： 10.1007/bf00558438

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  26 in total

1.  THE EFFECT OF CHLOROPHENOXYISOBUTYRIC ACID AND ETHINYL ESTRADIOL ON CHOLESTEROL TURNOVER.

Authors:  P J NESTEL; E Z HIRSCH; E A COUZENS
Journal:  J Clin Invest       Date:  1965-06       Impact factor: 14.808

2.  Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man.

Authors:  A Sedaghat; E H Ahrens
Journal:  Eur J Clin Invest       Date:  1975-04       Impact factor: 4.686

3.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

4.  Influence of free fatty acid concentration on drug binding to plasma albumin.

Authors:  A A Spector; E C Santos; J D Ashbrook; J E Fletcher
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

5.  Clofibrate for prevention of myocardial infarction.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1973-04-27       Impact factor: 1.909

6.  Acute muscular syndrome associated with administration of clofibrate.

Authors:  T Langer; R I Levy
Journal:  N Engl J Med       Date:  1968-10-17       Impact factor: 91.245

7.  Uremic lipemia: an unrecognized abnormality in triglyceride synthesis and removal.

Authors:  J D Bagdade; D Porte; F K Curtis; E L Bierman
Journal:  Trans Assoc Am Physicians       Date:  1968

8.  Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis.

Authors:  T P Gibson; W A Briggs; B J Boone
Journal:  J Lab Clin Med       Date:  1976-03

9.  Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.

Authors: 
Journal:  Br Med J       Date:  1971-12-25

10.  Control of clofibrate toxicity in uremic hypertriglyceridemia.

Authors:  A P Goldberg; D J Sherrard; L B Haas; J D Brunzell
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875
View more
  15 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 3.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation.

Authors:  R K Verbeeck; S M Wallace; G R Loewen
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

Review 6.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

7.  Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.

Authors:  U Abshagen; W Kösters; B Kaufmann; P D Lang
Journal:  Klin Wochenschr       Date:  1980-09-01

8.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

Authors:  Bengt Hamrén; Hans Ericsson; Ola Samuelsson; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

9.  Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.

Authors:  G Houin; R A Shastri; J Barre; B Pinchon; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

10.  Metabolism of amitriptyline in patients with chronic renal failure.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; B Hory; Y St Hillier; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.